The Patent Finder

Antyra, Inc.

Also on record
Records under this name other than patents Antyra, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 5 of 5 · Back to Antyra, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 6,875,741Insulin and IGF-1 Receptor Agonists and Antagonists
Lapsed on the fee record
Ended Apr 5, 2017 · Medium confidence
Lapsed on the fee recordEnded Apr 5, 2017Medium confidence
US 7,173,005Insulin and IGF-1 Receptor Agonists and Antagonists
Lapsed on the fee record
Ended Feb 6, 2015 · Medium confidence
Lapsed on the fee recordEnded Feb 6, 2015Medium confidence
US 7,148,193Compounds that bind to growth hormone receptor
Lapsed on the fee record
Ended Dec 12, 2010 · USPTO record
Lapsed on the fee recordEnded Dec 12, 2010USPTO record
US 7,056,679Target specific screening and its use for identifying target binders
Lapsed on the fee record
Ended Jun 6, 2010 · USPTO record
Lapsed on the fee recordEnded Jun 6, 2010USPTO record
US 6,387,879Compounds that bind growth to hormone receptor
Lapsed on the fee record
Ended May 14, 2010 · USPTO record
Lapsed on the fee recordEnded May 14, 2010USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited